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Abstract
Prenyl- and pyrano-xanthones derived from 1,3,6-trihydroxy-9H-xanthen-9-one, a basic backbone
of gambogic acid (GA), were synthesized and evaluated for in vitro cytotoxic effects against four
human cancer cell lines (KB, KBvin, A549, and DU-145) and anti-inflammatory activity toward
superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB.
Among them, prenylxanthones 7-13 were generally less active than pyranoxanthones 14-21 in
both anticancer and anti-inflammatory assays. Furthermore, two angular 3,3-
dimethypyranoxanthones (16 and 20) showed the greatest and selective activity against the KBvin
multidrug resistant (MDR) cell line with IC50 values of 0.9 and 0.8 μ g/mL, respectively. An
angular 3-methyl-3-prenylpyranoxanthone (17) selectively inhibited elastase release with 200
times more potency than phenylmethylsulfonyl fluoride (PMSF), the positive control.
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Gamboge resin, obtained from Garcinia hanburyi in Southeast Asia, has been used as a
coloring agent and folk medicine in China.1 Gambogic acid (GA) is a natural product
isolated from this resin. Its molecular structure features a unique 4-
oxatricyclo[4.3.1.0]decan-2-one ring system built on a xanthone backbone, and this unique
ring system is found only in natural products from the genus Garcinia.2 The biogenesis of
GA in nature must involve two different pathways, one similar to that of caged
benzophenones and the other to simple xanthones.3 Ollis and his colleagues reported that
GA can be synthesized from normal xanthone.4
Aside from its striking chemical architecture, pharmacological studies have revealed that
GA possesses potent antitumor activity both in vitro and in vivo,5 and GA has entered phase
I clinical trials in China for tolerance testing.6 In addition, the Garcinia genus is recognized
as a rich source of xanthone natural products with high pharmaceutical potential.7 GA
contains many functional groups; however, this complex lead compound may have a simpler
pharmacophoric moiety buried within its structure. If this pharmacophore can be clearly
identified, the resulting simpler molecule may have improved synthetic tractability and be
more useful. In order to elucidate the structure-activity relationship (SAR) correlations of
GA’s basic xanthone skeleton, a retro-synthetic analysis (Figure 1) suggested the design and
evaluation of the biological activities of 1,3,6-substituted xanthone derivatives would be
reasonable.
Xanthone compounds show potent biological activities, including growth inhibition of
various tumor cell lines,8 inhibition of human lymphocyte proliferation,9 and PKC
modulation,10 as well as antitumor11 and anti-inflammatory activities.12 These activities
have been associated with the compounds’ tricyclic scaffold depending on the nature and/or
position of the different substituents.13 A previous paper also revealed that several related
xanthones, including 1,3,6-trihydroxy-9H-xanthen-9-one, which is the basic skeleton of GA,
showed significant activity against sarcoma 180 tumor cells.14 Furthermore, recent literature
has also shown that prenylated dihydroxyxanthone derivatives exhibited tumor growth
inhibitory activity.3,13
Based on the above results, we designed and synthesized prenylated derivatives structurally
related to 1,3,6-trihydroxy-9H-xanthen-9-one, in an effort to find the optimal structural
features required for antitumor and anti-inflammatory effects. The synthesized compounds
4–21 have never been isolated as natural products. All new xanthone compounds were
assayed for in vitro cytotoxicity against four human cancer cell lines, KB (nasopharyngeal),
KBvin (multidrug-resistant nasopharyngeal over-expressing P-gp), A549 (lung), and
DU-145 (prostate), and for anti-inflammatory action in terms of superoxide anion generation
and elastase release by human neutrophils in response to fMLP/CB.
The synthetic methodologies used to synthesize the xanthone building blocks 4 and 5, and
their derivatives 6–21 are outlined in Schemes 1 and 2. 1,3,6-Trihydroxy-9H-xanthen-9-one
was originally prepared by condensation and cyclization reactions between phloroglucinols
and appropriately substituted salicylic acids with phosphorus oxychloride–zinc chloride as
catalyst.15 Later studies provided better results by using a mixture of phosphorus pentoxide–
methanesulfonic acid (Eaton’s reagent).16 Therefore, compounds 4 and 5 were synthesized
in good yields (90–95%) by the intramolecular oxidative coupling reaction between
phloroglucinol (3) and 2,4-dihydroxybenzoic acid (1) or 2-hydroxy-4-methoxybenzoic acid
(2), respectively, in the presence of Eaton’s reagent, and were used in the next step without
purification. Treatment of 4 with iodomethane in the presence of K2CO3/acetone gave 6
(84%). Prenylation of 4 with prenyl bromide in the presence of KOH furnished a mixture of
compounds 7–9, which were separated by silica gel column chromatography (7: 5.8%; 8:
4.2%; 9: 16%). The O-prenylated compounds 10–13 were prepared by reaction of 4 with
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prenyl bromide in the presence of both KOH and KI, followed again by chromatographic
separation (10: 4.2%; 11: 50%; 12: 5.8%; 13: 10%).
Cyclization of 4 to the desired linear pyranoxanthones 14 and 15 was accomplished by
reactions with prenal (3-methyl-2-butenal) and citral (3,7-dimethyl-2,6-octadienal),
respectively, in methanolic calcium hydroxide solution at rt to afford 85% and 70% yields,
respectively. For the angular pyranoxanthones 16 and 17, compound 4 was reacted with
prenal or citral at 140-150 ° C for 6 h resulting in yields of 95% and 93%, respectively.17
Dihydrodiolpyranoxanthones 18-21 were prepared by catalytic osmium tetroxide oxidation
of 14–17, respectively, using N-methylmorpholine N-oxide to regenerate the oxidizing agent
(18: 50%; 19: 45%; 20: 19%; 21: 22%).18
Cytotoxic activity
The synthesized compounds 4–21 can be divided into three classes, simple xanthones 4–6,
prenylxanthones 7–13, and pyranoxanthones 14–21. Table 1 lists the IC50 values obtained
with the test compounds compared to natural GA and the anticancer drug paclitaxel as a
positive control. The inhibitory effect of the test drugs on cell viability was measured by the
MTT colorimetric method as described previously.19
None of the three simple xanthones (4–6) showed significant cytotoxic effects against the
KBvin, A549, and DU-145 cancer cell lines. However, the addition of a prenyl group
increased the activity. Among the prenylxanthones 7–13, the C-prenylxanthones 7–9 (IC50
2.8 ~ 6.7 μ g/mL) were generally more active than the O-prenylxanthones 10–13 (IC50 3.7 ~
>10 μ g/mL) against the three tested cancer cell lines. Compound 10 with one O-prenyl
moiety was more active than compounds with two (12) or three (11, 13) groups. The
DU-145 cell line was most sensitive to these compounds (7–9: IC50 2.8 ~ 3.9 μ g/mL).
Among the pyranoxanthones 14–17, the angular 3-dimethylpyranoxanthone 16 showed a
notable IC50 value of 0.9 μ g/mL against the KBvin cancer cell line; however, it was much
less active against the KB, A549, and DU-125 cell lines (IC50 4.8 ~ 5.8 μ g/mL). The
corresponding angular 3-methyl-3-prenyl compound (17) and the two linear compounds (14
and 15) exhibited the same range of activity against all four cell lines (IC 50 4.4 ~ 6.6 μ g/
mL). Oxidation of the pyranoxanthones 14–17 to the dihydrodiolpyranoxanthones 18–21
generally resulted in decreased activity, with one exception. Compound 20, the dihydrodiol
analog of 16, retained the high activity against the KBvin cancer cell line with an IC50 value
of 0.8 μ g/mL. Overall, the 3-methyl compounds (14, 16, 18, and 20) exhibited greater
activity than the corresponding 3-prenyl compounds (15, 17, 19, and 21). Although most of
the synthetic compounds were inactive or much less active than the natural product GA,
compounds 16 and 20 were selective for and showed comparable activity with GA against
the KBvin cancer cell line, indicating that structural simplification could be a viable option
in the design of new chemotherapeutic agents from this compound class. Our research also
indicated that pyranoxanthones could have more potent cytotoxic effects than previously
discovered, as previous literature showed that prenylated xanthones had weak cytotoxicity
(IC50 values 50~ 80 μ M).20
Anti-inflammatory activity
Compounds 4–21 were also evaluated for anti-inflammatory action based on effects against
superoxide anion generation and elastase release by human neutrophils in response to fMLP/
CB. The assays were performed using established protocols,21 which are widely used to
identify potential anti-inflammatory compounds. Table 2 lists the results for the test
compounds, as well as diphenyleneiodonium (DPI) and phenylmethylsulfonyl fluoride
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(PMSF), included as positive controls for superoxide anion generation and elastase release,
respectively.
Xanthone 4 showed a selective inhibitory effect toward superoxide anion generation with an
IC50 value of 5.84 μ g/mL, while compounds 5 and 6 exhibited weak activity in both anti-
inflammatory assays. Among compounds 7–21, prenylxanthones 7–13 demonstrated weaker
effects than pyranoxanthones 14–21 in response to superoxide anion generation and elastase
release. Linear pyranoxanthone 14 was the most active compound, with IC50 values of 0.46
and 0.64 μ g/mL against superoxide anion generation and elastase release, respectively, and
angular pyranoxanthone 17 showed selective anti-inflammatory activity toward elastase
release with an IC50 value of 0.49 μ g/mL. Except for 16, 18, and 20, compounds 14–21
exhibited potent activity toward elastase release and were over 15-fold more potent than the
positive control PMSF.
In this investigation, we prepared a series of 1,3,6-substituted xanthones (4–6), as well as
prenyl- and pyrano-xanthone analogs (7–21),22 and evaluated SAR for their cytotoxic and
anti-inflammatory activities. In conclusion, among all screened compounds,
prenylxanthones 7–13 were less active than pyranoxanthones 14–21 in both anticancer and
anti-inflammatory assays. Two angular 3,3-dimethylpyranoxanthone analogs (16 and 20)
showed notable and selective activity against a multidrug resistant (MDR) cell line (KBvin)
with much lower activity against the parent cells (KB). A linear 3,3-
dimethylpyranoxanthone compound (14) exhibited significant potency in both anti-
inflammatory assays, and an angular 3-methyl-3-prenylpyranoxanthone compound (17) was
200-fold more potent than PMSF, the positive control, in the elastase release assay.
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for 6 h. The cooled solution was filtered and concentrated in vacuo. Purification on a flash column
(n-hexane/EtOAc, 85/15) yielded the desired compound (231 mg, 85%) as a yellow powder. mp:
118–120 ° C;1H NMR (CDCl3, 300 MHz): δ 3.87 and 3.92 (2 × 3H, each s), 6.31, 6.36, and 6.79
(3 × 1H, each s), 6.91 (1H, d, J = 8.7 Hz), 8.11 (1H, d, J = 8.7 Hz), 12.99 (1H, s).Prenylation of
1,3,6-trihydroxy-xanthen-9-one (4). Method 1: Prenyl bromide (243 μ L, 2 mmol) was added
dropwise over 10 min to a solution of 4 (244 mg, 1 mmol) and KOH (112 mg, 2 mmol) in H2O at
0 ° C under N2 atmosphere. The resulting mixture was stirred at 0 ° C for 24 h. During this time, a
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yellow solid precipitated from the mixture. The reaction mixture was quenched with pH 1 (HCl)
solution and extracted with EtOAc. The combined organic layers were washed with brine, dried
over MgSO4, filtered, and concentrated in vacuo. Purification on a flash column yielded 7, 8, and
9 (n-hexane/EtOAc, 95/5) successively.1,3,6-Trihydroxy-2,4-bis(3-methylbut-2-enyl)-9H-
xanthen-9-one (7). Yield: 5.8%; yellow oil; 1H NMR (CD3OD, 300 MHz): δ 1.67 and 1.89 (2 ×
6H, each s), 3.34 (2H, s), 3.43 (2H, d, J = 7.2 Hz), 5.15–5.19 (2 × 1H, m), 6.69 (1H, d, J = 2.1 Hz),
6.78 (1H, dd, J = 2.4, 8.7 Hz), 7.93 (1H, d, J = 8.7 Hz).1,3,6-Trihydroxy-2-(3-methylbut-2-
enyl)-9H-xanthen-9-one (8). Yield: 4.2% yield; yellow solid; 1H NMR (CD3OD, 300 MHz): δ
1.65 and 1.84 (2 × 3H, each s), 3.35 (2H, d, J = 6.9 Hz), 5.18–5.19 (1H, m), 6.14 (1H, s), 6.68 (1H,
d, J = 2.1 Hz), 6.76 (1H, dd, J = 2.1, 8.9 Hz), 7.89 (1H, d, J = 9.0 Hz).1,3,6-Trihydroxy-2,5-bis(3-
methylbut-2-enyl)-9H-xanthen-9-one (9). Yield: 16%; yellow solid; 1H NMR (CD3OD, 300
MHz): δ 1.67 (6H, s), 1.78 (2 × 3H, d, J = 4.2 Hz), 3.45 (2H, d, J = 6.3 Hz), 3.55 (2H, d, J = 6.3
Hz), 5.21–5.24 (2H, m), 6.19 (1H, s), 6.83 (1H, d, J = 8.7 Hz), 7.84 (1H, d, J = 9.0 Hz).Method 2:
To a solution of 4 (244 mg, 1 mmol), KI (332 mg, 2 mmol), and KOH (112 mg, 2 mmol) in DMF
at 0 ° C under N2 atmosphere, prenyl bromide (243 μ L, 2 mmol) was added dropwise over 10
min. The resulting mixture was then treated under conditions similar to Method 1. Purification on
a flash column yielded a mixture of 10 + 11 + 12 (n-hexane/EtOAc, 95/5) and pure 13 (n-hexane/
EtOAc, 90/10). The components of the mixture were then separated by preparative TLC (n-
hexane/EtOAc, 4/1).1,6-Dihydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one (10). Yield:
4.2%; yellow oil; 1H NMR (CDCl3, 300 MHz): δ 1.67 (2 × 3H, each s), 3.30 (2H, s), 3.43 (2H, d,
J = 7.2 Hz), 5.15-5.19 (1H, m), 6.13 (1H, d, J = 2.1 Hz), 6.26 (1H, d, J = 2.4 Hz), 6.69 (1H, d, J =
2.1 Hz), 6.78 (1H, dd, J = 2.4, 8.7 Hz), 7.93 (1H, d, J = 8.7 Hz).1-Hydroxy-2-(3-methylbut-2-
enyl)-3,6-bis(3-methylbut-2-enyloxy)-9H-xanthen-9-on e (11). Yield: 50%; yellow solid;1H NMR
(CDCl3, 300 MHz): δ 1.77–1.82 (12H, m), 1.85–1.90 (6H, m), 4.55–4.61 (6H, m), 5.49–5.51 (4H,
m), 6.35 (1H, d, J = 1.8 Hz), 6.40 (1H, d, J = 1.8 Hz), 6.78 (1H, d, J = 1.8 Hz), 6.89 (1H, dd, J =
2.1, 9.0 Hz), 8.08 (1H, d, J = 8.7 Hz), 13.19 (1H, s).1-Hydroxy-3,6-bis(3-methylbut-2-
enyloxy)-9H-xanthen-9-one (12). Yield: 5.8%; yellow solid; 1H NMR (CDCl3, 300 MHz): δ
1.77–1.82 (12H, m), 4.55–4.61 (4H, m), 5.49–5.51 (2H, m), 6.30 (1H, d, J = 1.8 Hz), 6.35 (1H, d,
J = 1.8 Hz), 6.78 (1H, d, J = 1.8 Hz), 6.89 (1H, dd, J = 2.1, 9.0 Hz), 8.08 (1H, d, J = 8.7 Hz), 13.27
(1H, s).1,3,6-Tris(3-methylbut-2-enyloxy)-9H-xanthen-9-one (13). Yield: 10%; yellow solid; 1H
NMR (CD3OD, 300 MHz): δ 1.78 (18H, s), 4.57 (4H, t, J = 6.5 Hz), 4.64 (2H, d, J = 6.3 Hz),
5.44–5.52 (3H, m), 6.28 (1H, d, J = 1.8 Hz), 6.38 (1H, d, J = 2.1 Hz), 6.73 (1H, d, J = 2.1 Hz),
6.82 (1H, dd, J = 2.1, 8.7 Hz), 7.97 (1H, d, J = 8.7 Hz).5,9-Dihydroxy-2,2-dimethylpyrano[3,2-
b]xanthen-6(2H)-one (14). Prenal (480 μ L, 5 mmol) was added to a stirring mixture of 4 (244 mg,
1 mmol) and Ca(OH)2 (150 mg, 2 mmol) in MeOH at rt. After continued stirring for 36 h at rt,
MeOH was removed under vacuum, and the reaction mixture was diluted with EtOAc. The
organic layer was washed with 2 N HCl, water, and brine, and dried over MgSO4. Purification on
a flash column (n-hexane/EtOAc, 90/10) afforded the desired compound (14, 85%) as a yellow
solid. mp: 228–230 ° C;1H NMR (CDCl3 + CD3OD, 300 MHz): δ 1.43 (6H, s), 5.63 and 6.27 (2 ×
1H, each s), 6.65 (1H, d, J = 10.2 Hz), 6.74 (1H, d, J = 1.8 Hz), 6.81 (1H, dd, J = 2.3, 8.9 Hz), 7.98
(1H, d, J = 8.7 Hz).5,9-Dihydroxy-2-methyl-2-(4-methylpent-3-enyl)pyrano[3,2-b]xanthen-6(2H)-
one (15). Under conditions similar to those described for the preparation of 14, compound 4 (244
mg, 1 mmol) and citral (860 μ L, 5 mmol) afforded 15 (70%) as a yellow solid. 1H NMR (CDCl3,
300 MHz): δ 1.35, 1.56, and 1.64 (3 × 3H, each s), 1.76–1.83 (2H, m), 2.06–2.10 (2H, m), 5.07–
5.10 (1H, m), 5.52 (1H, d, J = 10.2 Hz), 6.27 (1H, s), 6.72–6.85 (3H, m), 8.05 (1H, d, J = 9.0 Hz),
13.21 (1H, s).6,10-Dihydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (16). A stirring
mixture of 4 (244 mg, 1 mmol) and prenal (960 μ L, 10 mmol) was heated at 140–150 ° C for 6 h.
After cooling, the residue was purified on a flash column (n-hexane/EtOAc, 90/10) to afford 16
(295 mg, 95%) as a yellow powder. 1H NMR (CDCl3 + CD3OD, 300 MHz): δ 1.48 (6H, s), 5.66
(1H, d, J = 9.6 Hz), 6.16 (1H, s), 6.79–6.87 (3H, m), 8.02 (1H, d, J = 8.7 Hz).6,10-Dihydroxy-3-
methyl-3-(4-methylpent-3-enyl)pyrano[2,3-c]xanthen-7(3H)-one (17). Under conditions similar to
those described for the preparation of 16, compound 4 (244 mg, 1 mmol) and citral (1.7 mL, 10
mmol) afforded 17 (351.9 mg, 93%) as an amber-brown oil. 1H NMR (CDCl3, 300 MHz): δ 1.43,
1.56 and 1.64 (3 × 3H, each s), 1.78–1.83 (2H, m), 2.05–2.13 (2H, m), 5.05–5.10 (1H, m), 5.53
(1H, d, J = 10.2 Hz), 6.23 (1H, s), 6.80–6.86 (3H, m), 8.09 (1H, d, J = 9.0 Hz), 13.07 (1H, s).
3,4,5,9-Tetrahydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-b]xanthen-6(2H)-one (18). Compound
14 (84 mg, 0.22 mmol) was added to a solution of osmium tetroxide (2.5% in 2-methyl-2-
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propanol, 210 μ L) and 4-methylmorpholine N-oxide monohydrate (30 mg, 0.22 mmol) in t-
BuOH-THF-H2O (10:3:1, 14 mL). The reaction mixture was stirred at rt for 48 h. After addition of
saturated aqueous sodium bisulfate solution (30 mL), the mixture was stirred for 1 h and then
extracted with CH2Cl2. The combined organic layers were dried with MgSO4, filtered, and
evaporated in vacuo. Purification on a flash column (CH2Cl2/MeOH, 98/2) gave the desired
product (172.2 mg, 50%) as a yellow oil. 1H NMR (DMSO, 300 MHz): δ 1.41 (6H, s), 3.67 (1H,
d, J = 8.5 Hz), 5.02 (1H, d, J = 8.3 Hz), 6.68 (1H, d, J = 10.2 Hz), 6.77 (1H, d, J = 1.8 Hz), 6.80
(1H, dd, J = 2.3, 8.9 Hz), 7.94 (1H, d, J = 8.7 Hz).3,4,5,9-Tetrahydroxy-2-methyl-2-(4-
methylpent-3-enyl)-3,4-dihydropyrano[3,2-b]xa nthen-6(2H)-one (19). Using similar conditions to
those described for the preparation of 18, compound 15 (150 mg, 0.4 mmol) afforded 19 (186 mg,
45%) as a yellow solid. 1H NMR (DMSO, 300 MHz): δ 1.35, 1.56 and 1.64 (3 × 3H, each s),
1.76-1.83 (2H, m), 2.06–2.10 (2H, m), 5.07–5.10 (1H, m), 3.37 (1H, d, J = 8.5 Hz), 5.05 (1H, d, J
= 8.7 Hz), 5.52 (1H, d, J = 10.2 Hz), 6.27 (1H, s), 6.72-6.85 (3H, m), 8.05 (1H, d, J = 9.0 Hz),
13.17 (1H, s).1,2,6,10-Tetrahydroxy-3,3-dimethyl-2,3-dihydropyrano[2,3-c]xanthen-7(1H)-one
(20). Under similar conditions to those described for the preparation of 18, compound 16 (58.6
mg, 0.19 mmol) afforded 20 (172 mg, 50%) as an off-white solid. 1H NMR (DMSO, 300 MHz): δ
1.44 (6H, s), 3.26 (1H, d, J = 8.7 Hz), 5.03 (1H, d, J = 8.4 Hz), 6.14 (1H, s), 6.79–6.87 (3H, m),
8.03 (1H, d, J = 8.7 Hz).1,2,6,10-Tetrahydroxy-3-methyl-3-(4-methylpent-3-enyl)-2,3-
dihydropyrano[2,3-c]xa nthen-7(1H)-one (21). Under similar conditions to those described for the
preparation of 18, compound 17 (84 mg, 0.22 mmol) afforded 21 (194 mg, 47%) as yellow oil.1H
NMR (DMSO, 300 MHz): δ 1.45, 1.60 and 1.64 (3 × 3H, each s), 1.78-1.83 (2H, m), 2.05–2.13
(2H, m), 3.78 (1H, d, J = 8.7 Hz), 5.04 (1H, d, J = 8.7 Hz), 5.53 (1H, d, J = 10.2 Hz), 6.23 (1H, s),
6.80–6.86 (3H, m), 8.09 (1H, d, J = 9.0 Hz), 13.10 (1H, s).
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The retrosynthesis of gambogic acid.
Yen et al. Page 8














The synthesis of compounds 4–13.
Reagents: (a) P2O5-CH3SO3H, 80 ° C, 1 h (4: 92%; 5: 95%). (b) MeI, K2CO3, acetone,
reflux, 60 ° C, overnight (6, 85%). (c) (i) KOH, prenyl bromide, H2O, 0 ° C, 24 h (7: 5.8%;
8: 4.2%; 9: 16%;). (ii) KOH, KI, prenyl bromide, DMF, 0 ° C, 24 h (10: 4.2%; 11: 50%; 12:
5.8%; 13: 10%).
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The synthesis of pyranoxanthones 14–21.
Reagents and conditions: (a) prenal/citral, Ca(OH)2, MeOH, rt, 36 h (14: 85%; 15: 70%). (b)
prenal/citral, 140–150 ° C, 6 h (16: 95%; 17: 93%). (c) OsO4, NMMO, t-BuOH-THF-H2O
(10:3:1), rt, 48 h (18: 85%; 19: 70%; 20: 19%; 21: 22%).
Yen et al. Page 10

























Yen et al. Page 11
Table 1
Cytotoxicity of compounds 4–21.
Compound
Cancer cell line (IC50 value,a μg/mL)
KB KBvin A549 DU-145
4 NDb > 10 > 10 > 10
5 ND > 10 > 10 > 10
6 ND > 10 > 10 > 10
7 ND 6.7 6.4 3.9
8 ND 5.4 6.2 3.8
9 ND 4.4 5.0 2.8
10 ND 5.3 6.9 3.7
11 ND 7.5 7.9 4.3
12 ND > 10 9.3 > 10
13 ND > 10 > 10 6.3
14 4.6 5.5 5.8 4.4
15 6.2 6.0 6.6 6.2
16 4.8 0.9 5.8 5.1
17 5.3 5.7 5.1 5.2
18 6.3 6.8 5.9 5.4
19 > 10 > 10 > 10 > 10
20 > 10 0.8 9.9 6.7
21 > 10 > 10 > 10 > 10
GA 0.3 0.4 0.5 0.3
Paclitaxelc 1.6×10−3 1.1×10−3 1.9×10−3 2.4×10−3
a
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Table 2
Inhibitory effects of compounds on superoxide anion generation and elastase release by human neutrophils in
response to fMLP/CB.
Compound
Superoxide anion Elastase release
IC50 (μg/mL)a or (Inh%)a IC50 (μg/mL)a or (Inh%)a
4 5.84 ± 0.75 (16.0 ± 6.57)
5 (45.2 ± 3.22) (23.6 ± 1.24)
6 (31.3 ± 3.88)*** (26.5 ± 5.04)***
7 (101 ± 5.47)b (102 ± 1.94)b
8 (45.2 ± 0.43) (56.3 ± 3.42)
9 (31.6 ± 0.21) (67.2 ± 5.65)
10 20.2 ± 0.52 (4.21 ± 5.22)
11 (10.1 ± 2.73) (7.56±3.98)
12 (5.32 ± 0.12) (13.3 ± 5.32)
13 (64.3 ± 0.22) (54.9 ± 5.73)
14 0.46 ± 0.05 0.64 ± 0.22
15 5.43 ± 0.82 8.75± 0.69
16 3.97 ± 0.45 (18.4 ± 1.44)
17 35.6 ± 6.83c*** 0.49 ± 0.10
18 2.49 ± 0.38 (35.3 ± 1.59)***
19 4.30 ± 0.33 5.75 ± 0.17
20 (8.63 ± 6.95) (6.37 ± 5.04)
21 2.56 ± 0.28 8.46 ± 0.73
DPId 0.7 ± 0.4
PMSFd 131 ± 2.91
a
IC50 represents the 50% inhibitory concentration of the compound. If 50% inhibition was not reached at any test dose, the percentage of
inhibition obtained at a test dose of 10 μg/mL is given in parentheses (Inh%). Results are presented as mean ± S.E.M. (n = 3-5).
***
p < 0.001 compared with the control value.
b
7 alone elicited superoxide anion generation and elastase release by human neutrophils in the absence of fMLP/CB.
c
17 induced superoxide generation in the pretreatment of cytochalasin B.
d
DPI and PMSF were used as positive controls.
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